Division of Clinical Dentistry, School of Dentistry, International Medical University, Kuala Lumpur, Malaysia.
Department of Conservative Dentistry and Endodontics, Penang International Dental College, Butterworth, Penang, Malaysia.
Int Endod J. 2019 Jun;52(6):779-789. doi: 10.1111/iej.13072. Epub 2019 Feb 12.
The management of pain during root canal treatment is important. The aim of this systematic review and network meta-analysis was to identify the anaesthetic solution that would provide the best pulpal anaesthesia for inferior alveolar nerve blocks (IANB) treating mandibular teeth with irreversible pulpitis. Two electronic databases (PubMed and Scopus) were searched to identify studies up to October 2018. Randomized clinical trials comparing at least two anaesthetic solutions (lidocaine (lignocaine), articaine, bupivacaine, prilocaine or mepivacaine) used for IANB for treatment of irreversible pulpitis were included. The revised Cochrane risk of bias tool for randomized trials was used to assess the quality of the included studies. Pairwise meta-analysis, network meta-analysis using a random-effects model, and SUCRA ranking were performed. The network meta-analysis estimated the probability of each treatment performing best. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations approach. In total, 11 studies (n = 750) were included in the meta-analysis. The network meta-analysis revealed that only mepivacaine significantly increased the success rate of IANB compared to lidocaine (RR, 1.42 [95% CI 1.04-1.95]). However, no significant differences in the success rate of IANB were observed between mepivacaine and other anaesthetic agents (articaine and bupivacaine). Of all anaesthetic agents, mepivacaine (SUCRA = 0.81) ranked first in increasing the success rate of IANB, followed by prilocaine (SUCRA = 0.62), articaine (SUCRA = 0.54), bupivacaine (SUCRA = 0.41) and lidocaine (SUCRA = 0.13). The overall quality of evidence was very low to moderate. In conclusion, based on the evidence from the randomized clinical trials included in this review, mepivacaine with epinephrine demonstrated the highest probability of providing effective pulpal anaesthesia using IANB for teeth with irreversible pulpitis compared to prilocaine, articaine, bupivacaine and lidocaine. Further, high-quality clinical trials are needed to support the conclusion of this review.
根管治疗期间疼痛的管理很重要。本系统评价和网络荟萃分析的目的是确定哪种麻醉剂可提供用于治疗有不可逆性牙髓炎的下颌牙齿的下牙槽神经阻滞(IANB)的最佳牙髓麻醉效果。我们检索了两个电子数据库(PubMed 和 Scopus),以查找截至 2018 年 10 月的研究。纳入了比较至少两种麻醉剂(利多卡因(昔布卡因)、阿替卡因、布比卡因、丙胺卡因或甲哌卡因)用于治疗不可逆性牙髓炎的 IANB 的随机临床试验。使用修订后的 Cochrane 随机试验偏倚风险工具评估纳入研究的质量。进行了成对荟萃分析、使用随机效应模型的网络荟萃分析和 SUCRA 排名。网络荟萃分析估计了每种治疗方法的最佳表现概率。使用推荐评估、制定与评价分级方法评估证据质量。共有 11 项研究(n=750)纳入荟萃分析。网络荟萃分析显示,只有甲哌卡因与利多卡因相比,显著提高了 IANB 的成功率(RR,1.42[95%CI 1.04-1.95])。然而,在 IANB 的成功率方面,甲哌卡因与其他麻醉剂(阿替卡因和布比卡因)之间无显著差异。在所有麻醉剂中,甲哌卡因(SUCRA=0.81)在提高 IANB 成功率方面排名第一,其次是丙胺卡因(SUCRA=0.62)、阿替卡因(SUCRA=0.54)、布比卡因(SUCRA=0.41)和利多卡因(SUCRA=0.13)。总体证据质量为极低至中度。总之,根据本综述纳入的随机临床试验证据,与丙胺卡因、阿替卡因、布比卡因和利多卡因相比,含肾上腺素的甲哌卡因在用于治疗有不可逆性牙髓炎的牙齿的 IANB 中提供有效牙髓麻醉的可能性最高。此外,需要高质量的临床试验来支持本综述的结论。